Jason R. Dinges, PhD, JD
Investment Advisor, Morningside Technology Advisory LLC

Since February 2011, Dr. Dinges has served as an investment advisor at Morningside Technology Advisory LLC. Prior to that, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s Chemical, Biotechnology and Pharmaceutical practice group. Dr. Dinges also serves on the board of directors of various privately held biotechnology companies. Dr. Dinges received his PhD degree in genetics from Iowa State University and a JD degree from the University of Iowa College of Law.

Steven St. Peter, M.D.,MBA
Managing Director, JDRF T1D Fund

Steven St. Peter, M.D. joined the T1D Fund in 2019, following a seven-year career at Aratana Therapeutics  (NASDAQ: PETX), where he served as a Founder, President and Chief Executive Officer. Previously, as a Managing Director at MPM Capital, and through positions at Apax Partners and The Carlyle Group, Dr. St. Peter has founded, invested in and/or been involved with several life sciences companies including Align Technologies (NASDAQ: ALGN), Medpointe, ESP Pharma, SkinMedica, Omrix (NASDAQ: OMRI), Pharmathene (NYSE: PIP), Xanodyne, Syndax (NASDAQ: SNDX), EKR Therapeutics, Proteon (NASDAQ: PRTO), Rhythm (NASDAQ:RYTM). Dr. St. Peter has served on the Executive Committee & Board of Directors of the New England Venture Capital Association.  Dr. St. Peter holds an M.D. from Washington University, an M.B.A. in Finance from the Wharton School of the University of Pennsylvania and a B.A. in Chemistry from the University of Kansas, and had held the position of Assistant Clinical Professor of Medicine at Columbia University.

Jonathan Rigby, MBA
Independent Director

Mr. Rigby has three decades of experience building biopharmaceutical companies from early stages to IPO and acquisitions. He is currently President and Group CEO and a member of the Board of Immune Regulation Ltd, a company involved in developing novel treatments for autoimmune and allergic diseases. Previously, he established SteadyMed Therapeutics Inc, (NASDAQ IPO 2015, STDY), acquired by United Therapeutics (Nasdaq: UTHR) in 2018, and Zogenix, Inc. (NASDAQ IPO 2010, ZGNX). Prior to Zogenix, he worked at Aradigm Corp, a leader in the development of inhaled insulin, and held commercial and business development positions at Merck, Bristol Myers Squibb and Phillips Medical. Mr. Rigby currently serves on the Board of Directors of Thermalin Inc., and previously Xeris Pharmaceuticals (Nasdaq: XERS); and Chairman of CollPlant Biotechnologies, (Nasdaq: CLGN). He holds a Bachelor of Science Degree, with Honors, in Biological Sciences from Sheffield University, UK, and an MBA from Portsmouth University, UK.

Nandan Padukone, PhD, MBA
CEO

Dr. Padukone is an experienced biotechnology entrepreneur and executive having founded, built and advised several early and mid-stage biotechnology companies. Dr. Padukone has been Entrepreneur-in-Residence for the JDRF T1D Fund and led the development of the tech technology platform, clinical pipeline and corporate strategy of IM Therapeutics prior to its financing. He also served as Senior Vice President of Business Development of NeuroBo Pharmaceuticals, a biotech company focused on novel therapies for neurodegenerative diseases. Previously, Dr. Padukone served as the Senior Vice President of Innovation at the Joslin Diabetes Center, an affiliate of Harvard Medical School, where he led strategic R&D alliances, company creation, clinical trial services and healthcare partnerships in diabetes and related complications. Prior to Joslin, Dr. Padukone was President and CEO of Nuvera Biosciences, a biotech company he co-founded with MD Anderson Cancer Center to develop cancer diagnostics and personalized medicine for breast cancer. He is currently a Board Member of C2I, a biotechnology accelerator in the Greater Boston area and continues to advise entrepreneurs and early-stage ventures as a mentor with MassBio and the MIT Deshpande Center. Dr. Padukone holds a PhD in biochemical engineering from North Carolina State University, an MBA from the University of Denver, an MS in chemical engineering from SUNY Buffalo, and a Bachelor of Technology in chemical engineering from the Indian Institute of Technology of Mumbai.

Peter Gottlieb, MD
Co-founder, Chief Medical Officer

Peter Gottlieb, MD is Professor of Pediatrics and Medicine with tenure at the University of Colorado Health Science Center, and Director of Translational Research Unit at the Barbara Davis Center for Diabetes, and a practicing endocrinologist. Dr. Gottlieb is active in diabetes research, and currently serves as an Investigator for Type 1 Diabetes at Trialnet, Center Director for T1D Trialnet research at the University of Colorado, member of the Gastroparesis Clinical Research Consortium Data Safety Monitoring Board at NIDDK/Johns Hopkins, member of the Steering Committee of the T Cell Workshop at Immunology of Diabetes Society, and member of Viacyte Data Safety and Monitoring Board. He has previously served the Juvenile Diabetes Research Foundation as member and President of Board of Trustees Mountain States Region. Dr. Gottlieb currently serves on the Editorial Board of Diabetes Technology and Therapeutics, the European Journal of Clinical Investigation, and as a reviewer for Current Opinion in Diabetes and Endocrinology, the Journal of Clinical Endocrinology and Metabolism, Diabetes, and Diabetes Care, and has authored or co-authored numerous publications in peer reviewed journals.   Dr. Gottlieb earned a BS degree, Cum Laude, from University of Pennsylvania and MD degree from Robert Wood Johnson Medical School.

Ed Orr
Orr Land Company

Ed Orr is a 4th generation rancher, entrepreneur, and successful businessman based in Colorado. The reverence of the free enterprise system and capitalism, engrained by his hard-working ranch forefathers, set him on a course at a very young age of creating several business ventures which continue to thrive today. Ed’s personal life experience and knowledge of T1D has spurred his passion to see the prevention and cure of T1D and other autoimmune diseases. Ed’s concern of the effects of the complications of T1D on the growing T1D population has led him to be actively involved and a financial contributor to IMT from its inception as well as a contributor to T1D research at the Barbara Davis Center for Childhood Diabetes for several years.